Stocks & Financial News
Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts
Inmed Pharmaceuticals Inc. (NASDAQ: INM) Releases Favorable Results From INM-901 Preclinical AD Studies
studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function. In addition, molecular analysis data explains previously reported observations in behavioral studies on locomotion, memory and cognition. According to the announcement, several preclinical studies were conducted in well-characterized AD models and the company plans to accelerate the development of its AD program."The recent results demonstrating pharmacological effects in
in vivo
disease models continue to validate INM-901 as a potential treatment of AD," said InMed senior vice president of preclinical research and development Dr. Eric Hsu in the press release."We are particularly encouraged with indications that INM-901 has multiple potential mechanisms of action as a preferential signaling agonist for both cannabinoid 1 and cannabinoid 2 receptors, as well as impacting the peroxisome proliferator-activated receptor signaling pathway. There continues to be a major unmet medical need for this multi-factorial disease and differentiated therapeutic mechanisms may play an important role. We believe the development of INM-901 may address several pathological factors including neuroinflammation, neuroprotection and neuritogenesis."
To view the full press release, visit
About InMed Pharmaceuticals
Inc.
InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics with programs in Alzheimer's disease, age-related macular degeneration, glaucoma and epidermolysis bullosa. For more information, please visit .
NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company's newsroom at
About HempWire
HempWire
("HW") is a specialized communications platform with a focus on hemp-related news, information, and the latest developments in the hemp sector.
HempWire
is one of 60+ brands within
the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, HW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, HW brings its clients unparalleled recognition and brand awareness. HW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from HempWire, text"HempWire" to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit
Please see full terms of use and disclaimers on the HempWire website applicable to all content provided by HW, wherever published or re-published:
/Disclaimer
HempWire
Denver, Colorado
303.498.7722 Office
[email protected]
HempWire is powered by
IBN
MENAFN03012025000224011066ID1109051659
COMTEX_461500065/2604/2025-01-03T07:29:30